TSG-01
/ Shanghai Hongyitang Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 26, 2022
A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.
(clinicaltrials.gov)
- P2a | N=85 | Completed | Sponsor: Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd. | Recruiting ➔ Completed
Trial completion • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure
1 to 1
Of
1
Go to page
1